5-氟-2-(吡啶-2-基)-1H-苯并[D]咪唑 | 875468-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-氟-2-(吡啶-2-基)-1H-苯并[D]咪唑
• 英文名称: 5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole
• 英文别名: 5-Fluoro-2-(2-pyridyl)-1H-benzimidazole；6-fluoro-2-pyridin-2-yl-1H-benzimidazole
• CAS: 875468-81-8
• 化学式: C₁₂H₈FN₃
• mdl: MFCD12913332
• 分子量: 213.214
• InChiKey: AUSVDSQFCRIAEX-UHFFFAOYSA-N

物化性质

• 熔点：
  181 °C
• 沸点：
  431.4±43.0 °C(Predicted)
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-氟-2-(吡啶-2-基)-1H-苯并[D]咪唑 、 2-萘甲酰氯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以66%的产率得到(6-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl)(naphthalen-2-yl)methanone
  参考文献：
  名称：

  Design, Synthesis, Binding and Docking-Based 3D-QSAR Studies of 2-Pyridylbenzimidazoles—A New Family of High Affinity CB1 Cannabinoid Ligands

  摘要：

  基于我们之前对用于优化模板的CB1激动剂苯并咪唑14的研究，我们合理设计并合成了一系列新型2-吡啶基苯并咪唑衍生物。在本系列化合物中，21种化合物显示出高亲和力，Ki值在纳摩尔范围内。JM-39（化合物39）是该系列中活性最高的（KiCB1 = 0.53 nM），而化合物31和44显示出与WIN 55212-2相似的亲和力。基于获得的生物学数据进行了CoMFA分析，并得到了一个统计学上显著且具有高度预测价值的CoMFA模型（q2 = 0.710，r2 = 0.998，r2pred = 0.823）。

  DOI：

  10.3390/molecules18043972
• 作为产物：
  描述：

  2-吡啶甲酸 、 4-氟-1,2-苯二胺 在 PPA 作用下， 反应 2.0h， 以96%的产率得到5-氟-2-(吡啶-2-基)-1H-苯并[D]咪唑
  参考文献：
  名称：

  Metal-Mediated Inhibition of Escherichia coli Methionine Aminopeptidase:  Structure−Activity Relationships and Development of a Novel Scoring Function for Metal−Ligand Interactions

  摘要：

  We report the discovery of thiabendazole as a potent inhibitor (K-i = 0.4 mu M) of Escherichia coli methionine aminopeptidase (ecMetAP) and the synthesis and pharmacological evaluation of thiabendazole congeners with activity in the upper nanomolar range. Elucidation of the X-ray structure of ecMetAP in complex with thiabendazole and an unrelated inhibitor that was independently described by another group showed that that both compounds bind to an additional Coll ion at the entrance of the active site. This unexpected finding explains the inactivity of the compounds under in vivo conditions. It also allows us to discuss the structure-activity relationships of this series of compounds in a meaningful way, based upon docking runs with an auxiliary metal ion. We describe a new scoring function for the evaluation of metal-mediated inhibitor binding that, unlike the previously used scoring function implemented in the docking program, allows us to distinguish between active and inactive compounds. Finally, conclusions for the structure-based design of in vivo-active inhibitors of ecMetAP are drawn.

  DOI：

  10.1021/jm050476z

文献信息

• Synthesis of Pyridinyl-benzo[d]imidazole/Pyridinyl-benzo[d]thiazole Derivatives and their Yeast Glucose Uptake Activity In Vitro
  作者：Momin Khan、Riaz Ahmad、Gauhar Rehman、Naeem Gul、Sana Shah、Uzma Salar、Shahnaz Perveen、Khalid Mohammed Khan

  DOI：10.2174/1570180815666181004102209

  日期：2019.9.11

  Diabetes is the primary cause of fatality and disability all over the world, in recent past, we have reported various classes of compounds as anti-glycating agents and we have also reported benzimidazole and benzothiazole derivatives as a potential class of anti-glycating agents. This encouraged us to evaluate the pyridinyl benzimidazole/pyridinyl benzothiazole derivatives 1-27 for yeast glucose uptake activity.

  In the present study, an equimolar mixture of pyridine carboxaldehyde derivatives (1 mmol) and sodium metabisulphite (1 mmol) in DMF (10 mL) was stirred for 10 to 15 min, followed by addition of o-phenylene diamine/2-aminothiophenol (1 mmol) into it and refluxed for 3 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was poured into crushed ice. Precipitates were formed which were collected by filtration to produce compounds 1-27 in good yields. Recrystallization from methanol yielded pure crystals.

  Our present study showed that all compounds showed a varying degree of yeast glucose uptake activity in the range IC50 = 36.43-272.20 µM, compared to standard metronidazole (IC50 = 41.86 ± 0.09 µM). Compounds 5 (IC50 = 38.14 ± 0.17 µM), 6 (IC50 = 40.23 ± 0.20 µM), and 7 (IC50 = 36.43 ± 0.02 µM) showed an excellent yeast glucose uptake activity better than the standard.

  Pyridinyl benzimidazole/pyridinyl benzothiazole derivatives 1-27 were synthesized, structurally characterized, and evaluated for in vitro yeast glucose uptake activity. Compounds 5 (IC50 = 38.14 ± 0.17 µM), 6 (IC50 = 40.23 ± 0.20 µM), and 7 (IC50 = 36.43 ± 0.02 µM) demonstrated potent yeast glucose uptake activity as compared to standard metronidazole (IC50 = 41.86 ± 0.09 µM). This study identified a number of potential lead molecules which can be helpful in lowering the blood glucose level in hyperglycemia.

  背景：糖尿病是全球致死和致残的主要原因，最近，我们已报告各种类别的化合物作为抗糖基化剂，并且我们还报告苯并咪唑和苯并噻唑衍生物作为一种潜在的抗糖基化剂类。这激励我们评估吡啶基苯并咪唑/吡啶基苯并噻唑衍生物1-27对酵母葡萄糖摄取活性的作用。 方法：在本研究中，将吡啶羧醛衍生物（1 mmol）和亚硫酸钠（1 mmol）在DMF（10 mL）中等摩尔混合物搅拌10至15分钟，然后加入邻苯二胺/2-氨基硫酚（1 mmol）并回流3小时。通过薄层色谱监测反应进展。反应完成后，将反应混合物倒入碎冰中。形成沉淀，通过过滤收集，产生产率良好的化合物1-27。用甲醇再结晶得到纯晶体。 结果：我们的研究表明，所有化合物在酵母葡萄糖摄取活性范围内显示出不同程度的活性，IC50 = 36.43-272.20 µM，与标准甲硝唑（IC50 = 41.86 ± 0.09 µM）相比。化合物5（IC50 = 38.14 ± 0.17 µM）、6（IC50 = 40.23 ± 0.20 µM）和7（IC50 = 36.43 ± 0.02 µM）显示出优异的酵母葡萄糖摄取活性，优于标准物质。 结论：合成了吡啶基苯并咪唑/吡啶基苯并噻唑衍生物1-27，进行了结构表征，并评估了体外酵母葡萄糖摄取活性。化合物5（IC50 = 38.14 ± 0.17 µM）、6（IC50 = 40.23 ± 0.20 µM）和7（IC50 = 36.43 ± 0.02 µM）表现出强大的酵母葡萄糖摄取活性，与标准甲硝唑（IC50 = 41.86 ± 0.09 µM）相比。该研究确定了一系列潜在的先导分子，有助于降低高血糖水平。
• [EN] CANCER THERAPEUTICS<br/>[FR] TRAITEMENTS ANTICANCÉREUX
  申请人：UNIV VIRGINIA PATENT FOUND

  公开号：WO2016025744A1

  公开（公告）日：2016-02-18

  This invention relates to compounds that bind to wild-type CBFβ and inhibit CBFβ binding to RUNX proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type CBFβ from RUNX1 in cells, change occupancy of RUNX1 on target genes, and alter gene expression of RUNX1 target genes. These inhibitors show clear biological effects consistent with on-target RUNX protein activity. Pharmaceutical compositions containing a compound of the invention and a pharmaceutically acceptable carrier represent a separate embodiment of the invention. Another embodiment of the invention are methods of treating a RUNX-signaling-dependent cancer that expresses wild-type CBFβ in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention. In one embodiment, the cancer is selected from the group consisting of a RUNX-signaling-dependent leukemia that expresses wild-type CBFβ, lung cancer, bladder cancer, ovarian cancer, uterine cancer, endometrial cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, cervical cancer, lymphoma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, salivary gland cancer, bone cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, kidney cancer, skin cancer, melanoma, squamous cell carcinoma of the tongue, pleomorphic adenoma, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma, and/or adenocarcinoma. In another embodiment, the compounds of the invention can be used to treat a leukemia, lung cancer, ovarian cancer, and/or breast cancer.

  本发明涉及与野生型CBFβ结合并抑制CBFβ与RUNX蛋白结合的化合物。本发明的有效化合物以低微摩尔浓度抑制这种蛋白质-蛋白质相互作用，利用变构机制实现抑制，从细胞中置换野生型CBFβ从而改变RUNX1在靶基因上的占位率，改变RUNX1靶基因的基因表达。这些抑制剂表现出与靶向RUNX蛋白活性一致的明显生物学效应。含有本发明化合物和药学可接受载体的制药组合物代表该发明的另一实施形式。该发明的另一实施形式是通过向需要治疗的主体施用本发明化合物的治疗有效量来治疗表达野生型CBFβ的RUNX信号依赖性癌症。在一种实施形式中，该癌症被选自RUNX信号依赖性白血病，肺癌，膀胱癌，卵巢癌，子宫癌，子宫内膜癌，乳腺癌，肝癌，胰腺癌，胃癌，宫颈癌，淋巴瘤，白血病，急性髓性白血病，急性淋巴细胞白血病，涎腺癌，骨癌，脑癌，结肠癌，直肠癌，结直肠癌，肾癌，皮肤癌，黑色素瘤，舌鳞状细胞癌，多形性腺瘤，肝细胞癌，胰腺癌，鳞状细胞癌和/或腺癌。在另一实施形式中，本发明的化合物可用于治疗白血病，肺癌，卵巢癌和/或乳腺癌。
• INHIBITORS OF INV(16) LEUKEMIA
  申请人：The University of Virginia Patent Foundation

  公开号：EP3670509A1

  公开（公告）日：2020-06-24

  This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ∼12% of acute myeloid leukemia (AML). The inv(16) fusion results in expression of the CBFβ-SMMHC fusion protein in the blood cells of afflicted patients. The present invention provides compounds which inhibit the function of both CBFβ and the CBFβ-SMMHC fusion. These compounds block the growth of an inv(16) leukemia cell line as well as increase its apoptosis, while showing minimal effects against non inv(16) cell lines. As a mechanism to develop inhibitors with selectivity for the CBFβ-SMMHC fusion protein, the present invention further provides dimeric derivatives of these compounds which show both increased potency as well as selectivity for CBFβ-SMMHC. These compounds show potent inhibition of an inv(16) leukemia cell line with minimal effects on non inv(16) cell lines. Analysis of the pharmacokinetics of the developed compounds has made it possible to improve the lifetime of the compound in the plasma of mice to a level commensurate with long-term treatment.

  本发明描述了 inv(16) 融合的靶向小分子抑制剂的开发，inv(16) 融合是 12% 的急性髓性白血病（AML）的致病因子。inv（16）融合会导致患者血细胞中表达 CBFβ-SMMHC 融合蛋白。本发明提供了抑制 CBFβ 和 CBFβ-SMMHC 融合蛋白功能的化合物。这些化合物能阻断inv(16)白血病细胞系的生长，并增加其凋亡，同时对非inv(16)细胞系的影响极小。作为开发对 CBFβ-SMMHC 融合蛋白具有选择性的抑制剂的机制，本发明进一步提供了这些化合物的二聚衍生物，它们对 CBFβ-SMMHC 具有更高的效力和选择性。这些化合物对 inv(16) 白血病细胞系具有强效抑制作用，而对非 inv(16) 细胞系的影响极小。通过对所开发化合物的药代动力学分析，可以将化合物在小鼠血浆中的存活时间延长到与长期治疗相称的水平。
• Cancer therapeutics
  申请人：UNIVERSITY OF VIRGINIA PATENT FOUNDATION

  公开号：US10562890B2

  公开（公告）日：2020-02-18

  This invention relates to compounds that bind to wild-type CBFβ and inhibit CBFβ binding to RUNX proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type CBFβ from RUNX1 in cells, change occupancy of RUNX1 on target genes, and alter gene expression of RUNX1 target genes. These inhibitors show clear biological effects consistent with on-target RUNX protein activity. Pharmaceutical compositions containing a compound of the invention and a pharmaceutically acceptable carrier represent a separate embodiment of the invention. Another embodiment of the invention are methods of treating a RUNX-signaling-dependent cancer that expresses wild-type CBFβ in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention. In one embodiment, the cancer is selected from the group consisting of a RUNX-signaling-dependent leukemia that expresses wild-type CBFβ, lung cancer, bladder cancer, ovarian cancer, uterine cancer, endometrial cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, cervical cancer, lymphoma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, salivary gland cancer, bone cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, kidney cancer, skin cancer, melanoma, squamous cell carcinoma of the tongue, pleomorphic adenoma, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma, and/or adenocarcinoma. In another embodiment, the compounds of the invention can be used to treat a leukemia, lung cancer, ovarian cancer, and/or breast cancer.

  本发明涉及与野生型 CBFβ 结合并抑制 CBFβ 与 RUNX 蛋白结合的化合物。本发明的强效化合物可在低微摩尔浓度下抑制这种蛋白-蛋白相互作用，利用异构机制实现抑制作用，将细胞中的野生型 CBFβ 从 RUNX1 中置换出来，改变 RUNX1 对靶基因的占有率，并改变 RUNX1 靶基因的基因表达。这些抑制剂显示出与靶上 RUNX 蛋白活性一致的明显生物效应。含有本发明化合物和药学上可接受的载体的药物组合物代表了本发明的另一个实施方案。本发明的另一个实施方案是通过向有需要的受试者施用治疗有效量的本发明化合物来治疗表达野生型 CBFβ 的 RUNX 信号依赖性癌症的方法。在一个实施方案中，所述癌症选自由表达野生型 CBFβ 的 RUNX 信号依赖性白血病、肺癌、膀胱癌、卵巢癌、子宫癌、子宫内膜癌、乳腺癌、肝癌、胰腺癌、胃癌、宫颈癌、淋巴瘤、白血病、急性髓性白血病、急性淋巴细胞白血病、急性淋巴细胞白血病、急性髓细胞白血病、急性淋巴细胞白血病、唾液腺癌、骨癌、脑癌、结肠癌、直肠癌、结直肠癌、肾癌、皮肤癌、黑色素瘤、舌鳞癌、多形性腺瘤、肝细胞癌、胰腺癌、鳞状细胞癌和/或腺癌。在另一个实施方案中，本发明的化合物可用于治疗白血病、肺癌、卵巢癌和/或乳腺癌。
• CuI-catalyzed hydroxylation of aryl bromides under the assistance of 5-bromo-2-(1H-imidazol-2-yl)pyridine and related ligands
  作者：Jianhuan Jia、Chenglin Jiang、Xiaojing Zhang、Yongwen Jiang、Dawei Ma

  DOI：10.1016/j.tetlet.2011.08.059

  日期：2011.10

  A number of substituted 2-pyridin-2-yl-1H-benzoimidazoles and 2-(1H-imidazol-2-yl)pyridines were screened for promoting CuI-catalyzed hydroxylation of aryl bromides, which led to the discovery of the combination of Cut and 5-bromo-2-(1H-imidazol-2-yl)pyridine as an effective catalytic system for this transformation. Both electron-rich and electronic-deficient aryl bromides could be converted into the corresponding substituted phenols in good to excellent yields. (C) 2011 Elsevier Ltd. All rights reserved.